Incyte Corp. (INCY)
126.75
-1.25
(-0.98%)
USD |
NASDAQ |
Sep 04, 16:00
128.05
+1.30
(+1.03%)
Pre-Market: 20:00
Incyte Research and Development Expense (Quarterly) : 497.47M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 497.47M |
| March 31, 2026 | 515.90M |
| December 31, 2025 | 595.19M |
| September 30, 2025 | 489.46M |
| June 30, 2025 | 478.00M |
| March 31, 2025 | 437.28M |
| December 31, 2024 | 466.03M |
| September 30, 2024 | 573.17M |
| June 30, 2024 | 1.138B |
| March 31, 2024 | 429.26M |
| December 31, 2023 | 444.49M |
| September 30, 2023 | 375.71M |
| June 30, 2023 | 400.75M |
| March 31, 2023 | 406.64M |
| December 31, 2022 | 501.36M |
| September 30, 2022 | 384.01M |
| June 30, 2022 | 347.20M |
| March 31, 2022 | 353.37M |
| December 31, 2021 | 472.83M |
| September 30, 2021 | 334.94M |
| June 30, 2021 | 343.51M |
| March 31, 2021 | 306.90M |
| December 31, 2020 | 405.94M |
| September 30, 2020 | 438.11M |
| June 30, 2020 | 286.60M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.085B |
| December 31, 2019 | 312.87M |
| September 30, 2019 | 281.34M |
| June 30, 2019 | 289.36M |
| March 31, 2019 | 270.54M |
| December 31, 2018 | 304.24M |
| September 30, 2018 | 292.53M |
| June 30, 2018 | 298.09M |
| March 31, 2018 | 303.10M |
| December 31, 2017 | 446.94M |
| September 30, 2017 | 269.56M |
| June 30, 2017 | 201.79M |
| March 31, 2017 | 407.97M |
| December 31, 2016 | 161.58M |
| September 30, 2016 | 143.18M |
| June 30, 2016 | 120.27M |
| March 31, 2016 | 156.82M |
| December 31, 2015 | 116.63M |
| September 30, 2015 | 132.07M |
| June 30, 2015 | 112.44M |
| March 31, 2015 | 118.36M |
| December 31, 2014 | 98.72M |
| September 30, 2014 | 88.54M |
| June 30, 2014 | 84.68M |
| March 31, 2014 | 75.58M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | 90.29M |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| Eli Lilly & Co. | 3.819B |
| AbbVie, Inc. | 2.344B |
| Biogen, Inc. | 461.70M |